Contineum Therapeutics (Contineum Therapeutics) ROE % Adjusted to Book Value : 0.00% (As of Mar. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Contineum Therapeutics ROE % Adjusted to Book Value?

Contineum Therapeutics's ROE % for the quarter that ended in Mar. 2024 was 0.00%. Contineum Therapeutics's PB Ratio for the quarter that ended in Mar. 2024 was N/A. Contineum Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2024 was N/A.

Contineum Therapeutics ROE % Adjusted to Book Value Historical Data

The historical data trend for Contineum Therapeutics's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Contineum Therapeutics ROE % Adjusted to Book Value Chart

Contineum Therapeutics Annual Data

Trend

Dec21

Dec22

Dec23

ROE % Adjusted to Book Value

Negative Equity

Contineum Therapeutics Quarterly Data
	Dec21	Sep22	Dec22	Mar23	Sep23	Dec23	Mar24
ROE % Adjusted to Book Value	Get a 7-Day Free Trial			-	-	-	-	-

Competitive Comparison of Contineum Therapeutics's ROE % Adjusted to Book Value

For the Biotechnology subindustry, Contineum Therapeutics's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Contineum Therapeutics's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Contineum Therapeutics's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Contineum Therapeutics's ROE % Adjusted to Book Value falls into.

Contineum Therapeutics ROE % Adjusted to Book Value Calculation

Contineum Therapeutics's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	Negative Equity	/	N/A
	=	Negative Equity

Contineum Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2024 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	0.00%	/	N/A
	=	N/A

Contineum Therapeutics ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Contineum Therapeutics's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Contineum Therapeutics (Contineum Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Contineum Therapeutics Inc (NAS:CTNM) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

N/A

Address

10578 Science Center Drive, Suite 200, San Diego, CA, USA, 92121

Website

https://www.contineum-tx.com

Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.

Contineum Therapeutics (Contineum Therapeutics) Headlines

From GuruFocus

Contineum Therapeutics Announces Pricing of Initial Public Offering

By GlobeNewswire • 04-05-2024